Medical weight loss can be a transformative treatment for many patients who want to become slimmer

During the study, the study d A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before Intervention 1 Intervention 2 Not provided Anticipated Start Date Not provided Actual Start Date 2019-05-09 Anticipated Date of Last Follow-up 2021-03-05 Estimated Primary Completion Date Not provided Estimated Completion Date Not provided Actual Primary Completion Date 2019-12-12 Actual Completion Date 2020-01-17 Age Cohort Genders Accepts pregnant individuals Unspecified Accepts lactating individuals Unspecified Accepts healthy individuals No Inclusion Criteria: * Male or female, aged 18-75 years (both inclusive) at the time of signing informed consent * Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days prior to the day of screening * HbA1c of 7.0-10.0% (53.0-85.8 mmol/mol) (both inclusive) as assessed by central laboratory * Stable daily dose(s) for 90 days prior to the day of screening of any of the following antidiabetic drug(s) or combination regime(s): 1

Then on April 30, 2026, the FDA published a Federal Register notice proposing to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list
Video visits take place every six months
These can include nausea, diarrhea, constipation, or stomach discomfort, especially in the initial stages of treatment